DELFI Diagnostics Appoints Charles Newton to Board of Directors
DELFI Diagnostics has appointed Charles Newton to its Board of Directors as the company prepares for a pivotal data readout and FDA submission for its lead product, FirstLook Lung. Newton brings extensive experience in healthcare finance and leadership, which is expected to support DELFI's growth and commercialization efforts.
Tickers: $LYEL
Topics: biotech board appointment executive leadership FDA submission lung cancer screening